Phase II RCT: Efficacy and safety of Itepekimab in patients with moderate-to-severe asthma.

Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries on Twitter

Visual Abstract: Efficacy and Safety of Itepekimab for Moderate-to-Severe Asthma https://t.co/7mldcsSaeW pic.twitter.com/RlvE2Z1Tas

— NEJM (@NEJM) November 3, 2021

In this randomized trial, the monoclonal antibody itepekimab against interleukin-33 improved asthma control in patients with moderate-to-severe asthma. https://t.co/8yNcYumImy pic.twitter.com/YmMP0HjRvA

— NEJM (@NEJM) October 28, 2021